{"entity":{"id":"nct07651878","kind":"trial","name":"Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment","aka":[],"tldr":"A phase 1 trial of Vididencel run by Mendus, now recruiting.","summary":"Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment is a phase 1 interventional study registered as NCT07651878 by Mendus, with 24 participants planned, started 2026-04-14. Conditions recorded: CML (Chronic Myelogenous Leukemia). Interventions recorded: vididencel.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07651878","url":"https://clinicaltrials.gov/study/NCT07651878"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":["vididencel"],"companies":["mendus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07651878","phase":"1","setting":"An Open-Label, Single-Arm Phase 1 Trial to Evaluate the Safety, Tolerability and Efficacy of Vididencel in Chronic Phase Chronic Myeloid Leukemia Patients With Measurable Residual Disease Unable to Meet Requirements of Treatment Free Remission Under Tyrosine Kinase Inhibitor Treatment","sponsor":"Mendus","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07651878/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"drug":[{"id":"vididencel","kind":"drug","name":"Vididencel","route":"/drugs/vididencel/"}],"company":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"}]}}